Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
November 17, 2008

Scarring Alopecia Associated With Use of the Epidermal Growth Factor Receptor Inhibitor Gefitinib

Author Affiliations

Copyright 2008 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2008

Arch Dermatol. 2008;144(11):1524-1525. doi:10.1001/archderm.144.11.1524

Follicular eruptions are well-recognized adverse effects of epidermal growth factor receptor (EGFR) inhibitor therapy.1 Although alopecia is uncommon, mice with targeted disruption of the EGFR develop alopecia.2,3 We report the development of scarring alopecia associated with use of the EGFR inhibitor gefitinib (Iressa; AstraZeneca, Mississisauga, Ontario, Canada).

First Page Preview View Large
First page PDF preview
First page PDF preview